Researchers have announced that a newly completed Phase 1 study of a monoclonal antibody to rabies (RAB-1) showed positive results for the new therapy, which has the potential to save tens of thousands of lives each year in areas of the world hardest hit by rabies, where current standard treatments are often not available.